Clinicopathologic Features of Gastric Schwannoma: 8-Year Experience at a Single Institution in China

Kaixiong Tao, MD, PhD, Weilong Chang, PhD, Ende Zhao, MD, Rui Deng, PhD, Jinbo Gao, MD, KaiLin Cai, MD, Guobin Wang, MD, PhD, and Peng Zhang, MD

Abstract: To explore the clinicopathologic characteristics, diagnosis, treatment, and prognosis of gastric schwannoma in the imatinib era.

The clinicopathologic characteristics and postoperative outcomes of patients diagnosed with gastric schwannoma at our institution between January 2007 and February 2015 were retrospectively collected and analyzed.

The main patient complaint was epigastric pain or discomfort. Tumor sizes ranged from 15 to 80 mm (mean, 57.1 mm). In 17 patients, the tumors were located in the body of the stomach. A total of 20 patients were preoperatively misdiagnosed with a gastrointestinal stromal tumor. The rate of correct preoperative diagnosis was only 3.3%. All patients underwent surgical resection and showed strong S-100 protein positivity. It, however, is difficult to distinguish between schwannoma and GIST for whom diagnosis was confirmed after January 2007. Among these tumors, GIST represents approximately 80% of mesenchymal tumors of the gastrointestinal tract, with the stomach being the most common primary site. schwannoma rarely occurs in the gastrointestinal tract, representing only 3% of all gastrointestinal mesenchymal tumors. As with GIST, the most common primary site of schwannoma is also the stomach. It has been reported that gastric schwannoma represents 0.2% of all gastric tumors.

Previously, schwannoma and GIST were often misdiagnosed as leiomyoma or leiomyosarcoma. Only in the last decade, with new developments in immunohistochemistry, have schwannoma and GIST emerged as separate entities. The diagnosis of schwannoma is based on positive immunohistochemical staining for S-100 protein and negative results for CD117, CD34, desmin, and smooth muscle actin (SMA), whereas GIST is typically positive for CD117, DOG-1, and CD34 but negative for S-100 protein. It, however, is difficult to distinguish between gastric schwannoma and gastric GIST before surgery.

INTRODUCTION

According to the World Health Organization, gastric tumors are classified into 2 large categories, epithelial and nonepithelial, based on the cell origin. Epithelial neoplasms originate from the mucosa, whereas nonepithelial neoplasms arise from deep within the mucosa and are also termed mesenchymal tumors of the gastric wall. In contrast with epithelial tumors, mesenchymal tumors arise from submucosa, muscularis propria, or serosa, and they are often well circumscribed, with an intact overlying mucosa. Furthermore, mesenchymal tumors are rather rare, comprising 0.1% to 3% of all gastrointestinal tumors, and they consist of a spectrum of spindle cell tumors, mainly including gastrointestinal stromal tumor (GIST), leiomyoma or leiomyosarcoma, and schwannoma. Among these tumors, GIST represents approximately 80% of mesenchymal tumors of the gastrointestinal tract, with the stomach being the most common primary site. Schwannoma rarely occurs in the gastrointestinal tract, representing only 3% of all gastrointestinal mesenchymal tumors. As with GIST, the most common primary site of schwannoma is also the stomach. It has been reported that gastric schwannoma represents 0.2% of all gastric tumors.

METHODS

Thirty patients with gastric schwannoma treated at Wuhan Union Hospital between January 2007 and February 2015 were recruited for this study. The admission criterion was schwannoma of the stomach confirmed by pathologic examination at our institution. Patient data, including patient demographics, clinical presentation, preoperative imaging evaluation results, operative time, intraoperative blood loss amount, histopathology, postoperative complications, length of postoperative hospital stay, and follow-up results, were retrospectively analyzed. All patients provided written informed consent. The institutional

Abbreviations: EUS-FNA = endoscopic ultrasound-guided fine-needle aspiration, FDG = fluorodeoxyglucose, FDG-PET = 18F-fluorodeoxyglucose–positron emission tomography, GIST = gastrointestinal stromal tumor, SMA = smooth muscle actin.
review board and the ethics committee of Union Hospital deemed that an ethical review was not required for this retrospective analysis.

Statistical Analysis

Statistical analysis was performed using SPSS version 13.0 software (SPSS Inc., Chicago, IL). Significant differences were evaluated using Fisher exact test for categorical data and Student’s t-test for quantitative data. A P < 0.05 was considered to indicate a statistically significant difference.

RESULTS

Clinical Findings

The clinical data for the 30 patients (11 men and 19 women) are summarized in Table 1. The patients’ ages ranged from 38 to 79 years (mean age, 56.9 years; median age, 57 years). The main complaint was epigastric discomfort or pain, which was reported by 14 patients (46.7%). Nine patients (30%) were asymptomatic, and their tumors were detected incidentally by routine physical examination. Three patients (10%) presented with gastrointestinal bleeding, including melena (n = 3) and hematemesis (n = 1). In 2 patients, the tumors were incidentally discovered during surgery or examination for concomitant diseases. Other complaints included poor appetite (n = 1) and anemia because of chronic blood loss (n = 1).

Five patients had concomitant diseases, including cholelithiasis (n = 2), hepatic cyst, hepatic cavernous hemangioma, and duodenal GIST. None of the patients had a history of neurofibromatosis type 1 or type 2 syndrome.

Preoperative Evaluation

Endoscopy was performed on 22 patients at our hospital, with submucosal mass as the main finding. Mucosal ulceration was observed in 3 patients (13.6%). Eighteen patients underwent endoscopic ultrasonography, which demonstrated hypoechoic, submucosal masses arising from the fourth proper muscle layer. Furthermore, endoscopic biopsy was performed on 3 patients, but all were found to have normal mucosa. Another 2 patients underwent endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsy, and 1 was preoperatively diagnosed with gastric schwannoma.

TABLE 1. Clinicopathologic Characteristics of 30 Cases of Gastric Schwannoma

| Case Number | Age/Sex | Clinical Presentation | Size (mm) | Site | Preoperative Diagnosis | Operation                  |
|-------------|---------|-----------------------|-----------|------|------------------------|---------------------------|
| 1           | 57/F    | Epigastric discomfort | 80        | Gastric antrum    | Neoplasm                | Distal subtotal gastrectomy |
| 2           | 66/M    | Epigastric discomfort | 13        | Gastric body      | Leiomyoma               | Laparoscopic local excision |
| 3           | 57/M    | Epigastric discomfort, heartburn | 15 | Gastric antrum    | GIST                    | Distal subtotal gastrectomy |
| 4           | 40/F    | Epigastric pain, heartburn | 20 | Gastric body      | GIST                    | Laparoscopic wedge resection |
| 5           | 52/M    | Epigastric pain       | 40        | Gastric fundus    | GIST                    | Gastric wedge resection    |
| 6           | 57/F    | Abdominal pain        | 50        | Gastric antrum    | GIST                    | Distal subtotal gastrectomy |
| 7           | 45/M    | Asymptomatic          | 30        | Gastric fundus    | GIST                    | Laparoscopic wedge resection |
| 8           | 42/M    | Asymptomatic          | 22        | Gastric body      | GIST                    | Laparoscopic local excision |
| 9           | 61/F    | Gastrointestinal bleeding | 15 | Gastric antrum    | Duodenal GIST           | Distal subtotal gastrectomy |
| 10          | 72/F    | Epigastric discomfort | 50        | Gastric body      | Neoplasm                | Total gastrectomy          |
| 11          | 43/F    | Asymptomatic          | 33        | Gastric fundus    | GIST                    | Laparoscopic local excision |
| 12          | 50/F    | Melena                | 60        | Gastric antrum    | Schwannoma              | Distal subtotal gastrectomy |
| 13          | 38/M    | Epigastric discomfort | 28        | Gastric body      | GIST                    | Laparoscopic local excision |
| 14          | 76/M    | Anemia                | 60        | Gastric body      | Neoplasm                | Partial gastrectomy        |
| 15          | 70/M    | Asymptomatic          | 35        | Gastric body      | GIST                    | Laparoscopic local excision |
| 16          | 52/M    | Asymptomatic          | 42        | Gastric body      | GIST                    | Total gastrectomy          |
| 17          | 44/F    | Asymptomatic          | 60        | Gastric body      | GIST                    | Partial gastrectomy        |
| 18          | 39/F    | Epigastric pain       | 35        | Gastric antrum    | GIST                    | Laparoscopic local excision |
| 19          | 49/F    | Epigastric mass       | 50        | Gastric body      | GIST                    | Partial gastrectomy        |
| 20          | 69/M    | Hematemesis, melena   | 50        | Gastric body      | GIST                    | Local excision             |
| 21          | 73/F    | Poor appetite, heartburn | 25 | Gastric antrum    | GIST                    | Local excision             |
| 22          | 68/F    | Incidental            | 25        | Gastric fundus    | Protruding lesions      | Laparoscopic local excision |
| 23          | 71/M    | Epigastric pain       | 60        | Gastric body      | Neoplasm                | Laparoscopic wedge resection |
| 24          | 79/M    | Epigastric discomfort | 40        | Gastric body      | Protruding lesions      | Distal subtotal gastrectomy |
| 25          | 52/F    | Asymptomatic          | 40        | Gastric antrum    | GIST                    | Distal subtotal gastrectomy |
| 26          | 65/F    | Asymptomatic          | 25        | Gastric body      | GIST                    | Laparoscopic local excision |
| 27          | 54/F    | Melena                | 70        | Gastric body      | GIST                    | Total gastrectomy          |
| 28          | 49/M    | Abdominal pain        | 65        | Gastric body      | GIST                    | Laparoscopic partial gastrectomy |
| 29          | 60/F    | Asymptomatic          | 60        | Gastric fundus    | Epigastric mass         | Gastric wedge resection    |
| 30          | 57/F    | Epigastric pain       | 42        | Gastric body      | GIST                    | Laparoscopic partial gastrectomy |

GIST = gastrointestinal stromal tumor.
Computed tomography (CT) was performed for 16 patients, of whom 12 (75%) showed a homogeneous enhancement pattern. The tumor growth patterns were diverse and included endoluminal (n = 5), exogastric (n = 8), and intramural (n = 3) growth. High accumulation (maximal standardized uptake value, 6.43) coincident with the tumor was found in 1 patient by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET). Tumor markers were examined in 13 patients, and all were negative. Among these patients, the preoperative diagnoses were gastric GIST (n = 20), gastric neoplasm (n = 4), gastric protruding lesion (n = 2), gastric schwannoma (n = 1), gastric leiomyoma (n = 1), left epigastric mass (n = 1), and duodenal GIST (n = 1). Only 3.3% of the preoperative diagnoses matched the pathologic diagnoses.

Pathologic and Histologic Findings

The tumors tended to be located in the middle portion of the stomach, including the fundus, body, and antrum, in 5, 17, and 8 patients, respectively. The maximal diameters of the tumors ranged from 13 to 80 mm (mean, 41.3 mm). Ulceration of the mucosa was observed in 4 patients (13.3%). No necrosis, cystic changes, or calcification were detected in any of these tumors. Gross examination showed that the gastric schwannomas were homogeneous and firm and that the colors of the cut surfaces were yellow, yellowish, or gray-white (Figure 1). In all patients, the tumors were composed of spindle cells that were arranged mainly in small bundles or in a woven pattern, as observed by microscopic examination. Tumor cells were surrounded by a peripheral lymphoid cuff in 26 patients (86.7%), and germinal center formation was detected in 19 patients (63.3%) (Figure 2).

Immunohistochemical Findings and Genetic Studies

Immunohistochemical staining revealed strong S-100 protein positivity in all 30 of the examined patients (Figure 3). Twenty-seven patients were negative for CD34, whereas only 3 showed focal CD34 expression. All examined patients were negative for CD117, DOG-1, SMA, and desmin. The Ki-67 index was less than 2% in all patients, indicating a low proliferation rate. Mutational analysis was conducted for I patient (No. 9), in which KIT exons 9, 11, 13, and 17, and PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) exons 12 and 18 were evaluated. A mutation in KIT exon 11 was found in the duodenal GIST case, whereas no mutation was detected in the gastric schwannoma case.

Treatment

All patients underwent surgical treatment, including laparoscopic resection for 13 patients and open resection for 17. The surgical treatment included local excision or wedge resection (n = 11) and partial gastrectomy (n = 2) in the laparoscopic group, and local excision or wedge resection (n = 4), partial gastrectomy (n = 3), subtotal gastrectomy (n = 7), and total gastrectomy (n = 3) in the open surgery group. Four patients underwent additional procedures during treatment for gastric schwannoma. In the laparoscopic group, 1 patient underwent laparoscopic cholecystectomy, and 1 underwent left lateral hepatic lobectomy, and in the open surgery group, 1
reached nearly 2:1. This type of tumor is usually slow growing. 

Follow-Up

Follow-up was completed for 28 patients (93.3%). All of these patients were disease free, without recurrence or metastases, at a median follow-up time of 50 months (range, 12–97 months).

DISCUSSION

Schwannoma, also known as neurilemmoma or neurinoma, is a tumor originating from Schwann cells. Gastric schwannoma is a rare neoplasm that should be distinguished from other submucosal neoplasms of the stomach, such as GIST, leiomyoma or leiomyosarcoma, and lymphoma, some of which are malignant or have malignant potential. With recent advances in pathologic and immunohistochemical techniques, schwannoma and GIST have been recognized in the last 20 years as different primary gastrointestinal mesenchymal tumor entities. According to a recent classification, GIST accounts for approximately 80% of gastrointestinal mesenchymal tumors. Based on our data, gastric schwannoma is much less common than gastric GIST. At our institution, 267 patients were confirmed to have a gastric GIST during the same time period—that is, approximately 9 cases of gastric GIST were observed for each case of gastric schwannoma.

Gastric schwannoma occurs more frequently in patients ranging in age from 50 to 60 years and shows a greater prevalence in women; in our series, the female: male ratio reached nearly 2:1. This type of tumor is usually slow growing and is located in the body of the stomach along the lesser curvature. Owing to this indolent growth pattern, gastric schwannoma is asymptomatic and in most cases is incidentally discovered during routine medical checkup. Fujitake et al reported the identification of 13 patients (93%) via incidental findings upon cross-sectional imaging or endoscopy or during intraoperative visualization. In some cases, patients, however, may present with symptoms such as gastrointestinal bleeding, epigastric discomfort, or a palpable mass. In our study, approximately half of the patients presented with epigastric pain or discomfort; however, one-third of them were asymptomatic or were discovered incidentally, a finding that was not in accordance with those of previous studies.

Gastric schwannoma is usually detected preoperatively via endoscopy or cross-sectional imaging. Preoperative examination may be helpful for gaining the necessary information for preoperative diagnosis and for determining whether surgical resection is feasible. It, however, is very difficult to distinguish between gastric schwannoma and other types of gastric submucosal tumors by preoperative examination because of its rarity and lack of specific characteristics. On endoscopy, gastric schwannoma appears as an elevated submucosal mass that occasionally exhibits mucosal ulceration, making it indistinguishable from gastric GIST. Endoscopic ultrasonography scans can be used to delineate the full depth of a tumor and to direct needle biopsy. Zhong et al have noted that heterogeneous hypoechogenicity or isoechochogenicity, a well-demarcated margin, fourth-layer origination, and a lack of cystic change may be considered as useful findings for the diagnosis of gastric schwannoma. Endoscopic ultrasound-guided fine-needle aspiration is an accurate method for the diagnosis of gastric submucosal tumors, and the diagnostic yield has been reported to be 43.3% to 52%. In our study, EUS-FNA was performed on 2 patients, but only 1 diagnosis was confirmed as obtaining a sufficient amount of tissue was difficult. The National Comprehensive Cancer Network guidelines, however, do not recommend preoperative biopsy for primary resectable GIST, as there is a theoretical risk of tumor rupture and spread in association with poor prognosis. Therefore, considering the above information, preoperative biopsy is not routinely performed at our center.

Computed tomography is helpful for defining the exact location and extent of a tumor by revealing the displacement of the surrounding organs. On CT examination, gastric schwannoma exhibits homogeneous enhancement in most patients, and cystic changes are uncommon, consistent with our findings. Gastric GIST commonly, however, shows heterogeneous enhancement because of degenerative transformations, such as hemorrhage, necrosis, and cystic changes. 18F-fluorodeoxyglucose-positron emission tomography has been extensively used for the evaluation of various types of tumors, including GIST. Kamiyama et al have reported that fluorodeoxyglucose (FDG) uptake and the malignant potential of gastric GIST are strongly correlated. Increased FDG uptake, however, has also been reported in 3 patients of gastric schwannoma. The actual mechanism of high 18F-FDG uptake in gastric schwannoma has not yet been clarified in detail and may be related to intracellular glycolytic activity. Therefore, the value of FDG-PET as a preoperative diagnostic technique to differentiate gastric schwannoma from GIST is limited.

The definitive diagnosis of gastric schwannoma is determined by pathologic and immunohistochemical examination of surgical specimens. Schwannoma shows strong positive staining for S-100 protein and negative staining for CD117, CD34, desmin, and SMA. The S-100 staining pattern detected by

### Table 2: Comparisons of the Characteristics Between Laparoscopic and Open Resection of Gastric Schwannoma

| Variables                        | Laparoscopic Resection (n = 13) | Open Resection (n = 17) | P Value |
|----------------------------------|---------------------------------|-------------------------|---------|
| Male/female                      | 4/9                             | 7/10                    | 0.708   |
| Mean age (years)                 | 53                              | 60                      | 0.151   |
| Mean estimated blood loss (mL)   | 39                              | 164                     | 0.006   |
| Mean operation time (minutes)    | 104                             | 150                     | 0.006   |
| Mean postoperative hospital stay (days) | 10                              | 15                      | 0.004   |

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
immunohistochemistry is both nuclear and cytoplasmic. Gastric schwannoma may occasionally express CD34, but CD117, SMA, and desmin are uniformly negative. Macroscopically, gastric schwannoma has often been described as homogeneous, firm, or rubbery, and it rarely shows degenerative changes. Cystic changes, hemorrhage, and necrosis, however, are common in GIST. In the current study, no cystic change or necrosis was found, whereas ulceration was observed in only 4 gastric schwannoma patients. Microscopically, the tumors consisted of spindle cells with a prominent lymphoid cuff and were characterized by the absence of typical Verocay bodies, vascular hyalinization, and Antoni A and Antoni B areas. The genetic features of gastric schwannoma include a lack of KIT and PDGFRA mutations, in contrast with GIST.

In this study, the outcomes of the gastric schwannoma patients after surgical resection were excellent, with no recurrence, metastasis, or tumor-related mortality. Similarly, previous studies have indicated that gastric schwannoma is a rare gastric mesenchymal tumor with predominance in women. In fact, previous diagnoses of malignant schwannoma predated the application of modern immunohistochemistry techniques; therefore, gastric schwannoma could not then be reliably distinguished from GIST. In our study, the preoperative diagnosis in most of the patients was gastric GIST. Owing to the uncertainty of the preoperative diagnosis, the treatment of choice for gastric schwannoma remains complete surgical resection, similar to the treatment for GIST. The type of operation to perform depends on the tumor location, size, and relationship with the surrounding organs. Currently, gastric GIST is viewed as a good indication for laparoscopic resection, regardless of tumor size. Our data showed that laparoscopic surgery for most small- and moderate-sized gastric schwannomas was associated with less blood loss and a shorter postoperative hospital stay compared with open surgery. Moreover, it is crucial to avoid intraoperative tumor rupture. In all patients, an incision protection sleeve was used during the operation, and the specimen was placed into a specimen retrieval bag to prevent tumor peritoneal seeding or wound seeding.

CONCLUSIONS

Compared with gastric GIST, gastric schwannoma is a rarer gastric mesenchymal tumor with predominance in women in the imatinib era. This type of neoplasm is frequently located in the body of the stomach and predominantly occurs in older adults. Owing to their rare incidences and similar clinical manifestations, gastric schwannoma is typically misdiagnosed as gastric GIST before surgery. Complete margin-negative surgical resection is the curative treatment of choice. Laparoscopic resection of gastric schwannoma is considered safe and effective, and it may be the preferred resection technique for most patients. The long-term outcome is excellent, as this type of neoplasm is uniformly benign.

REFERENCES

1. Aalotten LA. Pathology and genetics tumour of the digestive system. World Health Organization Classification of Tumours. Lyon: IARC Press; 2000:37–38.
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382:973–983.
3. Kang HC, Menias CO, Gaballah AH, et al. Beyond the GIST: mesenchymal tumors of the stomach. Radiographics. 2013;33:1673–1690.
4. DeWitt J, Emerson RE, Sherman S, et al. Endoscopic ultrasound-guided trucut biopsy of gastrointestinal mesenchymal tumor. Surg Endosc. 2011;25:2192–2202.
5. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000;15:1293–1301.
6. Hou YY, Tan YS, Xu JF, et al. Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. Histopathology. 2006;48:536–545.
7. Daimaru Y, Kid o H, Hashimoto H, et al. Benign schwannoma of the gastrointestinal tract: a clinicopathologic and immunohistochemical study. Hum Pathol. 1988;19:257–264.
8. Melvin WS, Wilkinson MG. Gastric schwannoma. Clinical and pathologic considerations. Am Surg. 1993;59:293–296.
9. Miettinen M, Majidi M, Lasota J. Pathology and Diagnostic Criteria of Gastrointestinal Stromal Tumors (GISTs): A Review. Eur J Cancer. 2002;38:S39–S51.
10. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–1220.
11. Zheng L, Wu X, Kreis ME, et al. Clinicopathological and Immunohistochemical Characterisation of Gastric Schwannomas in 29 Cases. Gastroenterol Res Pract. 2014;2014:202960.
12. Voltaggio L, Murray R, Lasota J, et al. Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature. Hum Pathol. 2012;43:650–659.
13. Kwon MS, Lee SS, Ahn GH. Schwannomas of the gastrointestinal tract: clinicopathological features of 12 cases including a case of esophageal tumor compared with those of gastrointestinal stromal tumors and leiomyomas of the gastrointestinal tract. Pathol Res Pract. 2002;198:605–613.
14. Fujiwara S, Nakajima K, Nishida T, et al. Gastric schwannomas revisited: has precise preoperative diagnosis become feasible? Gastric Cancer. 2013;16:318–323.
15. Bruneton JN, Drouillard J, Roux P, et al. Neurogenic tumors of the stomach. Report of 18 cases and review of the literature. Rofo. 1983;139:192–198.
16. Zhong DD, Wang CH, Xu JH, et al. Endoscopic ultrasound features of gastric schwannomas with radiological correlation: a case series report. World J Gastroenterol. 2012;18:7397–7401.
17. Mekky MA, Yamao K, Sawaki A, et al. Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. Gastrointest Endosc. 2010;71:913–919.
18. Fernandez-Esparrach G, Sendino O, Sole M, et al. Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: a randomized crossover study. Endoscopy. 2010;42:292–299.
19. Arolfo S, Teggia PM, Nano M. Gastrointestinal stromal tumors and leiomyomas of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. Histopathology. 2011;25:2192–2202.
20. Hong HS, Ha HK, Won HJ, et al. Gastric schwannomas: radiological features with endoscopic and pathological correlation. Clin Radiol. 2008;63:536–542.
21. Levy AD, Quiles AM, Miettinen M, et al. Gastrointestinal schwannomas: CT features with clinicopathologic correlation. AJR Am J Roentgenol. 2005;184:797–802.
22. Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics. 2003;23:283–304456,532.
23. Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28:247–253.
24. Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. *World J Surg.* 2005;29:1429–1435.

25. Ohno T, Ogata K, Kogure N, et al. Gastric schwannomas show an obviously increased fluorodeoxyglucose uptake in positron emission tomography: report of two cases. *Surg Today.* 2011;41:1133–1137.

26. Komatsu D, Koide N, Hiraga R, et al. Gastric schwannoma exhibiting increased fluorodeoxyglucose uptake. *Gastric Cancer.* 2009;12:225–228.

27. Shimada Y, Sawada S, Hojo S, et al. Glucose transporter 3 and 1 may facilitate high uptake of 18F-FDG in gastric schwannoma. *Clin Nucl Med.* 2013;38:e417–e420.

28. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol.* 2005;29:52–68.

29. Prevot S, Bienvenu L, Vaillant JC, et al. Benign schwannoma of the digestive tract: a clinicopathologic and immunohistochemical study of five cases, including a case of esophageal tumor. *Am J Surg Pathol.* 1999;23:431–436.

30. Sarlomo-Rikala M, Miettinen M. Gastric schwannoma: a clinicopathological analysis of six cases. *Histopathology.* 1995;27:355–360.

31. Goh BK, Chow PK, Kesavan S, et al. Intraabdominal schwannomas: a single institution experience. *J Gastrointest Surg.* 2008;12:756–760.

32. Honda M, Hiki N, Nunobe S, et al. Long-term and surgical outcomes of laparoscopic surgery for gastric gastrointestinal stromal tumors. *Surg Endosc.* 2014;28:2317–2322.

33. Lin J, Huang C, Zheng C, et al. Laparoscopic versus open gastric resection for larger than 5 cm primary gastric gastrointestinal stromal tumors (GIST): a size-matched comparison. *Surg Endosc.* 2014;28:2577–2583.